Tauriga Sciences Inc (OTCMKTS:TAUG) has had a slew of recent developments that have propelled the stock higher. In the last week alone, the stock has climbed over 50%. At the beginning for April, TAUG announced that it had appointed Frank Orlowski to its advisory board. Frank has over 20 years of experience in the pharmaceutical industry. In addition it also announced that it appointed Keith Berman to its board of directors as well.
We first wrote about TAUG on March 28, 2016 and the stock has climbed 150% since we featured it. Be sure to sign up for our free newsletter and alerts to not miss the next pick.
In other exciting developments, the company closed a private equity placement for $105,500. The terms of this private placement are as follows: $0.004 per share of common stock with a related three year warrant for 40% of each share of common stock purchased and an exercise price of $0.01 per share. The funds will be used for the ongoing litigation against its prior auditor in the latter part of the article.
Chief Executive Officer Set Shaw expressed, “We are very pleased to have attracted such a qualified director with a breadth of knowledge in both the technical areas of the life sciences space as well as complex corporate litigation. We look forward to working closely with Mr. Berman as Tauriga continues to strive towards a successful future for its shareholders.” Keith M. Berman brings more than 35 years’ experience in the healthcare field, having worked with such companies as Technicon Corporation and Boehringer-Mannheim Corporation. Mr. Berman also was the founder of Cymedix, the operating division of the former Ramp Corp
In recent developments, Tauriga Sciences Inc (OTCMKTS:TAUG) has provided an update regarding its ongoing litigation its previous audit firm. . The lawsuit against Cowan Gunteski was initially filed by the TAUG on November 4, 2015 and subsequent to that there was a lengthy mediation process. In total, TAUG is seeking over $3 million in monetary awards for damages; however, this figure could increase as time elapses. On a positive note, Cowan Gunteski has insurance coverage for its malpractice. The company plans to proceed with going to trial; however, a settlement may be the most likely outcome.
The CEO of the company stated, “The company has suffered a tremendous amount of damage from the malpractice as well as the subsequent conduct committed by Cowan Gunteski. Management has fought tirelessly to keep the Company afloat during this difficult period and is thankful for the efforts and dedication of its outstanding legal team. The Company is confident in the strength and merits of its legal arguments and looks forward to trying this case in Federal Court as soon as practicable.”
In other developments, TAUG has announced that it has signed an engagement letter with a new independent auditing firm. It hopes to become a fully reporting company in the next several months by filing 10-Ks with SEC with the help of the independent auditing firm. TAUG has been forced to re-audit its financial statements due to its ongoing litigation with prior auditing firm. It hopes by updating and filing with SEC it can up-list to a more senior exchange to gain access to more liquidity and more favorable financing.
TAUG is a diversified life sciences company focused on generating profitable revenues through its present and future holdings. The mission of TAUG is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. Its business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses.
TAUG is currently trading at a $8 million market valuation. The company has provided an update regarding its pending legal actions against its prior audit firm. A settlement could net the company significant monetary compensation for damages.
We have a Monster Pick Coming. Subscribe Right Now!
We will be updating on TAUG when more details emerge so make sure you are subscribed to Microcapspot so you know what’s going on with TAUG.
Disclosure: we hold no position in TAUG either long or short at the publication of this article and we have not been compensated for this article.
Subscribe To Microcap Newsletter
By entering your email address you agree to get email updates from Microcap Spotlight. We'll respect your privacy and unsubscribe at any time.